Comprehensive Analysis of Oxalate Homeostasis in Calcium Oxalate Kidney Stone Formers
- Institution
- University of Alabama at Birmingham, AL
- Principal investigator
- Sonia Fargue
- Funding
- $590K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
SUMMARY Urinary oxalate excretion is a key risk factor in the formation of calcium oxalate kidney stones, the most common type of kidney stone, a disease that affects 9% of the US population. Therapeutic development for prevention of calcium oxalate kidney stone disease is hampered by our incomplete understanding of the factors leading to the increased urinary oxalate pool in many patients with calcium oxalate kidney stones. Environmental and lifestyle factors as well as dietary and metabolic, or endogenous, factors may all play a role, but the interplay between them has clouded the interpretation of the oxalate focused studies that have been done in kidney stone formers. Our preliminary data and published studies suggest there is both an increased synthesis of oxalate and a greater gastrointestinal absorption of oxalate in calcium oxalate kidney stone formers. These warrant confirmation and the underlying mechanisms need to be defined. The frequency of colonization with Oxalobacter formigenes, a gut commensal oxalate degrading bacterium, is substantially lower in calcium oxalate kidney stone formers and its absence has been linked with increased kidney stone risk. Colonization with Oxalobacter formigenes leads to reduced urinary oxalate excretion in healthy volunteers. Whether colonization with this organism is possible in calcium oxalate kidney stone formers and leads to reduced urinary oxalate excretion warrants study. Our hypothesis is that increased endogenous oxalate synthesis and increased gastrointestinal absorption of oxalate via greater transport capacity and higher bioavailablity due to decreased microbial oxalate degradation in the gut lead to a greater influx of oxalate and increased urinary oxalate excretion. This proposal aims to 1/ demonstrate that endogenous oxalate synthesis is increased in idiopathic calcium oxalate kidney stone formers using 13C-isotope oxalate infusion to quantify oxalate production and determine the contribution of different oxalate precursors by oral dosing with 13C-glycolate and 13C-ascorbic acid; 2/ confirm that gastrointestinal oxalate absorption is higher in idiopathic calcium oxalate kidney stone formers and define the driving mechanisms by using a combination of low and high oxalate diets and 13C-oxalate oral dosing coupled with sugar functional intestinal permeability tests that will identify gut segments and type of transport involved; 3/ demonstrate that the colonization of Oxalobacter formigenes in idiopathic calcium oxalate kidney stone formers is possible, sustainable, and results in a reduction of urinary oxalate excretion. We expect this proposal to identify mechanisms playing a role in the increased urinary oxalate pool in idiopathic calcium oxalate kidney stones patients; develop tools to investigate these mechanisms; provide a potential treatment for lowering urinary oxalate excretion by colonization with Oxalobacter formigenes. This in turn may lead to the development of targeted therapies to be tested in clinical trials for treating those afflicted with calcium oxalate kidney stones.
LOADING MOONBASE SCORE
Questions for University of Alabama at Birmingham
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NSF · University of Alabama at Birmingham61
High-Entropy Alloy Superconductors under High Pressures
Yogesh K Vohra · $457K · 2023–2026
- NIH · University of Alabama at Birmingham59
Dihydroxyacetone exposure induces metabolic reprogramming and mitochondrial dysfunction
Natalie Rose Gassman · $306K · 2021–2025
- NIH · University of Alabama at Birmingham49
Distinct Glycophenotypes with Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Galactose-Deficient IgA1, the Main Autoantigen in IgA Nephropathy
Colin Robert Reily · $448K · 2023–2027